CancerCell
Previews
Next-GenerationGenomicPro ling
ofHepatocellularAdenomas:ANewEraofIndividualizedPatientCare
JensU.Marquardt1,2,*andSnorriS.Thorgeirsson1,*
ofExperimentalCarcinogenesis(LEC),CenterforCancerResearch,NationalCancerInstitute,NIH,37ConventDrive,
Room4146,Bethesda,MD20892,USA
2DepartmentofMedicineI,JohannesGutenbergUniversity,55131Mainz,Germany
*Correspondence:marquarj@uni-mainz.de(J.U.M.),snorri_thorgeirsson@nih.gov(S.S.T.)doc.guandang.net
1Laboratory
Hepatocellularadenomas(HCAs)areclinicallyrelevantbenignliverlesionsthatcommonlyoccurinwomenonhormonalcontraceptives.InthisissueofCancerCell,Pilatiandcolleaguespresentanintegrativemulti-‘‘omics’’-basedanalysisofHCAandidentifyrecurrentgeneticalterationsassociatedwithadenoma-carci-nomatransitionandnewdrugabletargets.
Hepatocellularadenomas(HCAs)arehormone-sensitivemonoclonalbenignliverlesionsthatareassociatedwiththeuseofestrogenrichcontraceptivesorandrogen-containingsteroidanabolics.Mostfrequently,HCAsdevelopinnoncir-rhoticlivers,displayingacleargenderdisparitywithafemale/maleratioof9:1(Bioulac-Sageetal.,2011).Also,HCAsarerarelyassociatedwithhereditarymetabolicdisorders(i.e.,glycogenstor-agedefects).Althoughonlyasmallfrac-tionofHCAscauseclinicalsymptomsorundergomalignanttransformation,accu-rateevaluationofthisprobabilityisessen-tialforappropriatetreatment.
Signi cantprogresshasbeenachievedonthebasisofmutationalanalysesaswellasdistincthistologicalandradiolog-icalfeatures,pioneeredbystrongFrenchconsortia,resultingintheclassi cationofHCAsintofoursubtypes(Naultetal.,2013a):
(1)Hepatocytenuclearfactor1(HNF1a)-mutatedHCAs(HHCAs)constitute30%to40%ofalladenomasmainlycharacter-izedbydisruptedglucoseandlipidmeta-bolism,leadingtosteatosisanddown-regulationofLFABP.Genomicanalysesidenti edrecurrentlossesofheterozygos-ityatchromosome12q,withsubsequentanalysesthatrevealedbiallelicsomaticmutationsintheHNF1Agene.HHCAsareassociatedwithmaturity-onsetdia-betestype3,amonogenicnon-insulin-dependentdiabetes(Bluteauetal.,2002).(2)Telangiectatic/in ammatoryade-nomas(IHCAs)harboractivatingin-framesomaticmutationsingp130-encoding
IL6STor,lessfrequently,inGNASorSTAT3.IHCAsshowpolymorphicin- ammatoryin ltrates,dystrophicvessels,andsinusoidaldilatationsandconstitutearound40%to50%ofalladenomas(Rebouissouetal.,2009).ThecardinalfeatureofIHCAsistheactivationoftheJAK/STATpathway(Pilatietal.,2011);however,concomitantmutationsinb-cat-eninareobservedinupto50%ofIHCAs(i.e.,bIHCA).(3)b-catenin-mutatedadenomas(bHCAs)constituteapproximately10%to15%ofallHCAs,displayingcytologicalabnormalitiesincludingacinarpatternandcholestaticchanges.Activatingmutationsofb-cateninaremainlylocalizedinexon3.Interestingly,mutationsinthepathway,whileoverlappingwithothersubtypes(e.g.,bIHCA),aremutuallyexclusivewithHNF1Amutations.bHCAshavethehigh-estpotentialofmalignanttransformationintohepatocellularcarcinoma(HCC),rangingfrom0%–18%andrepresentingtwothirdsofalltransformedHCAs(Fargesetal.,2011).Interestingly,preva-lenceofmalignancyinbHCAistentimeshigherinmenthanwomenandisasso-ciatedwithmetabolicchanges.Identi- cationofthissubtypehasthemostimportantclinicalimplicationsforpatientmanagement(e.g.,withdrawalofandro-gensorresection).
(4)Around10%ofHCAsshownospe-ci cmorphologicalorimmunophenotypi-calpatternsandare,therefore,termedunclassi edHCA(UHCA).
InthisissueofCancerCell,Pilatietal.(2014)reportfurtherre nementofthemo-lecularunderstandingofHCAsbyusingintegrativegenomicanalysescombiningmultiplemolecularlayers.DuetoalargecollectionofrepresentativeHCAsamplesandtheuseofnext-generationsequencingincombinationwithothergenomictech-nologies,theresultsprovideseveralexcitingclinicalaswellasmechanisticin-ferences(Figure1).
Thestudyincluded250tumorsfrom195patientsandisthelargesttodate.Thecohortwaswellbalancedregardinggender(male:female,1:6),etiology(84%oralcontraceptives),andsubtypes(HHCA,29%;bHCA,14%;bIHCA,16%;IHCA,31%;UHCA,10%).Thestudyalsoincluded18HCAswithmalignanttrans-formationintoHCC.Theauthorsinitiallyscreened35tumorsbyawhole-exomesequencingapproach.Theanalysesyieldedtheidenti cationandsubsequentvalidationof264/508somaticmutationsaspotentiallyproteinaltering.Interest-ingly,comparedtoothermalignantsolidtumorssuchascolon,lung,andpancreaticcancerswithanaverageof33to66proteindamagingmutations(Vogelsteinetal.,2013)and,inparticular,HCCwitharound41mutations,thegenomesofHCAsappearrelativelystablewithanaveragerateofdamagingmutationsof7.5.Amongthemutations,onlyCTNNB1,IL6ST,HNF1A,andFRKwererecurrentlymutatedinatleastthreeHCAs.Ofnote,pairedana-lysesofdifferenttumorsinthesamepatientssuggestedanindependentdevel-opmentofthelesions,potentiallyindi-catingthatmultiplebiopsiesmightbewar-rantedinpatientswithmultifocal

disease.
CancerCell25,April14,2014ª2014ElsevierInc.409
2.1 规范的治疗方法是制定个体化综合治疗方案的基础 366 原发性肝癌的治疗方法主要包括肝脏部分切除、肝脏移 植、局部消融治疗、经肝动脉化疗栓塞(TACE)、放射治 ...
$, " EF2 · $5$ · 专家论坛· · 原发性肝癌要按个体化采用以手术 为主的综合治疗陈孝平 裘法祖 吴在德 [$*5] 无癌栓以及肿瘤生物学特性等方面的不...
要想提高肝癌病人 的生存率,必须按照规范化治疗指导方案进行, 除了严格掌握HAI/HAE/THSAE治疗的适应症和禁 忌症以外,重要的是制定合理的“个体化”方案, 尤其是...
在过去的数年里,发达国家通过早期筛查、早期 诊断和多种治疗手段,使得肝癌的预后有了明显提 高。临床应根据患者情况,选择个体化治疗方案。参考文献:〔1〕RamponeB,...
常用于肝癌的中药复方, 实际上可能包括抗炎、抗凝、抗血管生成、提高免疫等 的综合作用。中医辨证论治也可能有助于探索整体水平 的个体化治疗。实验研究发现含5味...
叶胜龙 教授 第二分册 原发性肝癌 1989 1999 第一部分 背 景 第二部分原发...制订最佳的个体化治疗方案,有计划、合理地选择或者联 合应用外科手术、肝动脉...
肝癌介入治疗规范化方案_医药卫生_专业资料。一、肝癌综合性介入治疗规范 原发...3、制定优化的“个体化”方案 根据每位患者肝肿瘤的类型和大小、有无门静脉癌...
检测 C 收集技术及其在个体化药物治疗方面的作用’关键词 #肿 瘤 * 循环肿瘤...肝癌 用 QI-% 分离 $%$ 最先 是在肝癌患者身上进行的$ 用这种方 法认定...
肿瘤治疗的最优化与个体化复旦大学附属中山医院 杨秉辉 思考 您是否了解现行的...那 你说他是肝癌,那这个病人有黄疸,有肿块,有甲胎蛋白的阳性,有超声波的占...
根据肝癌各级治疗目标与治疗方 法之间的关系,建立肝癌治疗新模式。结果:提出了全方位、系统化、规范化、个体化、动 结果: 结果 态式、经济型的肝癌治疗设计的新...
热门文档